Elizabeth Smyth, MD, Cambridge University Hospitals, Cambridge, UK, discusses the results of a Phase I trial for using CAR-T therapy to treat previously-treated solid tumors in the digestive tract. The CAR T-cells were engineered to target Claudin 18.2, a protein expressed on epithelial tight junctions which is exposed on tumor cells. 37 patients participated in the trial, of which most had gastric or GEJ tumors. Response rates were 49% in the whole population and 61% in patients with gastric or GEJ tumors. Progression-free survival was around 6 months, median overall survival was around 9 months, and toxicity was low. This interview took place at the European Society for Medical Oncology (ESMO) 2021 congress.
Dr Smyth reports personal financial interests (lecture honoraria, advisory boards, travel support) from AMAL Therapeutics, Astra Zeneca, Astellas, Beigene, BMS, Celgene, Elsevier, Everest Clinical Research, Five Prime Therapeutics, Gritstone Oncology, Merck, Pfizer, Roche, Servier, Zymeworks.